Precipio Inc
PRPO22.190USD
-1.000-4.31%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
38.74MMarket Cap
LossP/E TTM
More Details of Precipio Inc Company
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Precipio Inc Info
Ticker SymbolPRPO
Company namePrecipio Inc
IPO dateJul 18, 2000
CEODanieli (Ilan S)
Number of employees54
Security typeOrdinary Share
Fiscal year-endJul 18
Address4 Science Park
CityNEW HAVEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06511
Phone12037877888
Websitehttps://www.precipiodx.com/
Ticker SymbolPRPO
IPO dateJul 18, 2000
CEODanieli (Ilan S)
Company Executives of Precipio Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
6.86K
+11.56%
Ms. Christina R. Valauri
Ms. Christina R. Valauri
Independent Director
Independent Director
--
--
Dr. Ayman A. Mohamed, M.D.
Dr. Ayman A. Mohamed, M.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ilan S. Danieli
Mr. Ilan S. Danieli
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
--
--
Mr. Matthew Gage
Mr. Matthew Gage
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Jeffrey Cossman, M.D.
Dr. Jeffrey Cossman, M.D.
Independent Director
Independent Director
--
--
Mr. Ahmed Zaki Sabet
Mr. Ahmed Zaki Sabet
Chief Operations Officer
Chief Operations Officer
--
--
Dick Sandberg ,
Dick Sandberg ,
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David S. Cohen
Mr. David S. Cohen
Independent Director
Independent Director
--
--
Mr. Ronald A. (Ron) Andrews, Jr.
Mr. Ronald A. (Ron) Andrews, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
6.86K
+11.56%
Ms. Christina R. Valauri
Ms. Christina R. Valauri
Independent Director
Independent Director
--
--
Dr. Ayman A. Mohamed, M.D.
Dr. Ayman A. Mohamed, M.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ilan S. Danieli
Mr. Ilan S. Danieli
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
--
--
Mr. Matthew Gage
Mr. Matthew Gage
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Jeffrey Cossman, M.D.
Dr. Jeffrey Cossman, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Third party payers
2.69M
47.70%
Medicare
2.28M
40.58%
Other
624.00K
11.09%
Contract diagnostics
23.00K
0.41%
Medicaid
8.00K
0.14%
Self-pay
5.00K
0.09%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Third party payers
2.69M
47.70%
Medicare
2.28M
40.58%
Other
624.00K
11.09%
Contract diagnostics
23.00K
0.41%
Medicaid
8.00K
0.14%
Self-pay
5.00K
0.09%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AMH Equity, Ltd.
8.56%
Eklund (David A)
4.81%
Topline Capital Management, LLC
3.72%
Cohen (David Seth)
3.06%
BlackRock Institutional Trust Company, N.A.
1.65%
Other
78.20%
Shareholders
Shareholders
Proportion
AMH Equity, Ltd.
8.56%
Eklund (David A)
4.81%
Topline Capital Management, LLC
3.72%
Cohen (David Seth)
3.06%
BlackRock Institutional Trust Company, N.A.
1.65%
Other
78.20%
Shareholder Types
Shareholders
Proportion
Hedge Fund
13.02%
Individual Investor
12.00%
Investment Advisor
5.24%
Investment Advisor/Hedge Fund
0.98%
Other
68.76%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
24
199.00K
12.29%
+26.19K
2025Q2
39
319.42K
21.11%
+23.29K
2025Q1
41
305.07K
20.32%
+66.28K
2024Q4
41
257.51K
17.37%
+21.31K
2024Q3
43
252.17K
17.06%
+16.33K
2024Q2
43
225.77K
15.35%
+14.07K
2024Q1
44
184.55K
13.08%
-29.31K
2023Q4
43
211.34K
15.03%
-9.34K
2023Q3
42
197.75K
14.39%
-78.27K
2023Q2
43
266.64K
19.86%
+97.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AMH Equity, Ltd.
130.00K
8.03%
+102.11K
+366.12%
Sep 19, 2025
Eklund (David A)
84.25K
5.2%
+84.25K
--
Jul 25, 2024
Cohen (David Seth)
52.94K
3.27%
+888.00
+1.71%
Jul 16, 2025
BlackRock Institutional Trust Company, N.A.
28.91K
1.79%
--
--
Jun 30, 2025
Sandberg (Richard A)
25.18K
1.55%
+17.95K
+248.20%
Apr 21, 2025
The Vanguard Group, Inc.
17.64K
1.09%
--
--
Jun 30, 2025
Andrews (Ronald Asbury)
15.23K
0.94%
+676.00
+4.65%
Jul 16, 2025
Geode Capital Management, L.L.C.
15.22K
0.94%
+122.00
+0.81%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 21, 2023
Merger
20→1
Sep 21, 2023
Merger
20→1
Sep 21, 2023
Merger
20→1
Sep 21, 2023
Merger
20→1
Date
Type
Ratio
Sep 21, 2023
Merger
20→1
Sep 21, 2023
Merger
20→1
Sep 21, 2023
Merger
20→1
Sep 21, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Precipio Inc?
The top five shareholders of Precipio Inc are:
AMH Equity, Ltd. holds 130.00K shares, accounting for 8.03% of the total shares.
Eklund (David A) holds 84.25K shares, accounting for 5.20% of the total shares.
Cohen (David Seth) holds 52.94K shares, accounting for 3.27% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 28.91K shares, accounting for 1.79% of the total shares.
Sandberg (Richard A) holds 25.18K shares, accounting for 1.55% of the total shares.
AMH Equity, Ltd. holds 130.00K shares, accounting for 8.03% of the total shares.
Eklund (David A) holds 84.25K shares, accounting for 5.20% of the total shares.
Cohen (David Seth) holds 52.94K shares, accounting for 3.27% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 28.91K shares, accounting for 1.79% of the total shares.
Sandberg (Richard A) holds 25.18K shares, accounting for 1.55% of the total shares.
What are the top three shareholder types of Precipio Inc?
The top three shareholder types of Precipio Inc are:
AMH Equity, Ltd.
Eklund (David A)
Topline Capital Management, LLC
AMH Equity, Ltd.
Eklund (David A)
Topline Capital Management, LLC
How many institutions hold shares of Precipio Inc (PRPO)?
As of 2025Q3, 24 institutions hold shares of Precipio Inc, with a combined market value of approximately 199.00K, accounting for 12.29% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.82%.
What is the biggest source of revenue for Precipio Inc?
In FY2025Q2, the Third party payers business generated the highest revenue for Precipio Inc, amounting to 2.69M and accounting for 47.70% of total revenue.
